VIDEO: ‘No difference’ between ustekinumab, tofacitinib for steroid-free remission in UC
Click Here to Manage Email Alerts
CHARLOTTE, N.C. — In a Healio video exclusive, Rahul Dalal, MD, MPH, reported ustekinumab and tofacitinib yielded similar safety and efficacy in the treatment of a small subset of adult patients with ulcerative colitis.
Specifically, among 97 patients who received ustekinumab (Stelara, Janssen) and 69 patients who received tofacitinib (Xeljanz, Pfizer), 48.9% and 56.1% achieved steroid-free clinical remission at 52 weeks with similar drug survival between groups (adjusted HR = 1.26; 95% CI, 0.74-2.15).
Dalal, an IBD fellow at Brigham and Women’s Hospital, noted these results reaffirmed the need for larger, prospective studies comparing the effectiveness of these therapies.
“Overall, we found that there were some baseline differences with higher endoscopic severity and C-reactive protein in the tofacitinib group but after adjusting for differences in disease characteristics, we found no difference in achieving steroid free remission at 52 weeks or 12 weeks,” he said. “Both treatments were effective with more than 45% of patients achieving these endpoints.”
Collapse
Dalal R, et al. Abstract S718: One-Year Comparative Effectiveness of Ustekinumab vs Tofacitinib for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure. Presented at: ACG Annual Scientific Meeting; Oct. 21-2, 2022; Charlotte (hybrid meeting).
Read more about
Click Here to Manage Email Alerts